Theravance Biopharma Inc Total Liabilities

Latest as of December 2025: $188.85 Million USD

Theravance Biopharma Inc total liabilities. Based on the latest financial reports, Theravance Biopharma Inc (TBPH) has total liabilities worth $188.85 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Theravance Biopharma Inc to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Theravance Biopharma Inc (2011–2025)

Total liabilities of Theravance Biopharma Inc from 2011 to 2025. This chart illustrates how Theravance Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Theravance Biopharma Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.

Theravance Biopharma Inc Competitors by Total Liabilities

The table below lists competitors of Theravance Biopharma Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Whirlpool China Co Ltd SHG:600983	China	CN¥2.84 Billion
Aarti Pharmalabs Limited NSE:AARTIPHARM	India	Rs-19.90 Billion
Jiangxi Guotai Civilian SHG:603977	China	CN¥2.43 Billion
Jiangsu Asia Pacific Light Alloy Technology Co Ltd SHE:002540	China	CN¥2.64 Billion
Indus Holding AG XETRA:INH	Germany	€1.24 Billion
Cisen Pharmaceutical Co Ltd SHG:603367	China	CN¥1.41 Billion
Kayne Anderson BDC, Inc. NYSE:KBDC	USA	$1.17 Billion
Dios Fastigheter AB ST:DIOS	Sweden	Skr21.52 Billion

Liability Composition Analysis (2011–2025)

This chart breaks down Theravance Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see TBPH total asset value.

Liquidity & Leverage Metrics

Theravance Biopharma Inc Total Liabilities Ratios Explained

Theravance Biopharma Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	10.93	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.64	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.39	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Theravance Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Theravance Biopharma Inc (2011–2025)

The table below shows the annual total liabilities of Theravance Biopharma Inc from 2011 to 2025.

Year	Total Liabilities	Change
2025-12-31	$188.85 Million	+5.73%
2024-12-31	$178.62 Million	+5.69%
2023-12-31	$169.00 Million	+2.06%
2022-12-31	$165.60 Million	-76.79%
2021-12-31	$713.39 Million	-7.69%
2020-12-31	$772.81 Million	+22.15%
2019-12-31	$632.67 Million	+3.41%
2018-12-31	$611.82 Million	+87.55%
2017-12-31	$326.22 Million	+12.87%
2016-12-31	$289.02 Million	+406.60%
2015-12-31	$57.05 Million	+18.90%
2014-12-31	$47.98 Million	+13.67%
2013-12-31	$42.21 Million	+86.19%
2012-12-31	$22.67 Million	-85.33%
2011-12-31	$154.54 Million	--

About Theravance Biopharma Inc

NASDAQ:TBPH USA Biotechnology

Market Cap

$876.92 Million

Market Cap Rank

#9203 Global

#2616 in USA

Share Price

$17.03

Change (1 day)

+0.00%

52-Week Range

$13.57 - $20.74

All Time High

$42.56